Compare NVEC & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | XOMA |
|---|---|---|
| Founded | 1989 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.8M | 308.6M |
| IPO Year | 1995 | N/A |
| Metric | NVEC | XOMA |
|---|---|---|
| Price | $66.58 | $30.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 21.7K | ★ 98.0K |
| Earning Date | 05-06-2026 | 03-18-2026 |
| Dividend Yield | ★ 5.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | ★ $25,874,694.00 | N/A |
| Revenue This Year | N/A | $24.95 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | $31.94 | ★ $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.50 | $18.40 |
| 52 Week High | $82.30 | $39.92 |
| Indicator | NVEC | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 69.04 |
| Support Level | $64.17 | $23.92 |
| Resistance Level | $66.89 | $30.79 |
| Average True Range (ATR) | 2.70 | 1.54 |
| MACD | -0.16 | 0.36 |
| Stochastic Oscillator | 26.00 | 82.01 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.